Abstract
The inhibition of α-glucosidase and α-amylase, enzymes involved in the digestion of carbohydrates, can significantly reduce the post-prandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type 2 diabetic and borderline patients. Currently, there is renewed interest in plant-based medicines and functional foods modulating physiological effects in the prevention and cure of diabetes and obesity. The plant kingdom is a wide field to search for natural effective oral hypoglycaemic agents that have slight or no side effects. More than ca. 1200 plant species have been recorded to be used empirically worldwide for their alleged hypoglycaemic activity. Therefore, natural α-glucosidase and α-amylase inhibitors from plant sources offer an attractive strategy for the control of hyperglycaemia. This article reviews recent data on plant extracts and isolated natural compounds that are being tested for their hypoglycaemic activity, highlights ongoing research and considers the future perspectives.
Keywords: Diabetes, Post-prandial Hyperglycaemia, α-Glucosidase, α-Amylase, Extract, Natural compounds
Mini-Reviews in Medicinal Chemistry
Title: Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update
Volume: 10 Issue: 4
Author(s): R. Tundis, M.R. Loizzo and F. Menichini
Affiliation:
Keywords: Diabetes, Post-prandial Hyperglycaemia, α-Glucosidase, α-Amylase, Extract, Natural compounds
Abstract: The inhibition of α-glucosidase and α-amylase, enzymes involved in the digestion of carbohydrates, can significantly reduce the post-prandial increase of blood glucose and therefore can be an important strategy in the management of blood glucose level in type 2 diabetic and borderline patients. Currently, there is renewed interest in plant-based medicines and functional foods modulating physiological effects in the prevention and cure of diabetes and obesity. The plant kingdom is a wide field to search for natural effective oral hypoglycaemic agents that have slight or no side effects. More than ca. 1200 plant species have been recorded to be used empirically worldwide for their alleged hypoglycaemic activity. Therefore, natural α-glucosidase and α-amylase inhibitors from plant sources offer an attractive strategy for the control of hyperglycaemia. This article reviews recent data on plant extracts and isolated natural compounds that are being tested for their hypoglycaemic activity, highlights ongoing research and considers the future perspectives.
Export Options
About this article
Cite this article as:
Tundis R., Loizzo M.R. and Menichini F., Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update, Mini-Reviews in Medicinal Chemistry 2010; 10 (4) . https://dx.doi.org/10.2174/138955710791331007
DOI https://dx.doi.org/10.2174/138955710791331007 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of 5-HT1A Receptor in Cancer as a New Opportunity in Medicinal Chemistry
Current Medicinal Chemistry Mas Receptor Agonists as Novel Antihypertensive Agents
Current Hypertension Reviews Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry High Throughput Metabolomics in Clinical Studies: Review and New Applications to Remote Ischemic Preconditioning
Current Topics in Medicinal Chemistry Central Hemodynamics in Risk Assessment Strategies: Additive Value Over and Above Brachial Blood Pressure
Current Pharmaceutical Design Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Aqueous Extract of <i>Cola nitida</i> and <i>Garcinia kola</i> Synergistically Enhances Hippocampal-hypothalamic Glutamate and Na+ /K+ -ATPase Activity in Male Wistar Rats
Current Drug Discovery Technologies An Overview of Non-Neural Sources of Calcitonin Gene-Related Peptide
Current Medicinal Chemistry Development and Validation of a Stability-Indicating HPLC Method for the Assay of Carvedilol in Pure and Tablet Dosage Forms
Current Pharmaceutical Analysis Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Chemistry and Effects of Brainstem Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Effects of Diabetic HDL on Endothelial Cell Function
Cardiovascular & Hematological Disorders-Drug Targets Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Recent Applications of Grape Polyphenols in Foods, Beverages and Supplements
Recent Patents on Food, Nutrition & Agriculture Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Impact of Short-Term Educational and Behavioral Therapy on Childhood Obesity
Vascular Disease Prevention (Discontinued) Formulation and Ex Vivo Evaluation of Buccal Tablets of Isradipine in a β- Cyclodextrin Complex to Improve the Photostability
Current Drug Therapy Designing and Evaluating Health Systems Level Hypertension Control Interventions for African-Americans: Lessons from a Pooled Analysis of Three Cluster Randomized Trials
Current Hypertension Reviews Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design